Search

Your search keyword '"Taraswi Mitra Ghosh"' showing total 20 results

Search Constraints

Start Over You searched for: Author "Taraswi Mitra Ghosh" Remove constraint Author: "Taraswi Mitra Ghosh"
20 results on '"Taraswi Mitra Ghosh"'

Search Results

1. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer

2. Genome-wide study of response to platinum, taxane, and combination therapy in ovarian cancer: in vitro phenotypes, inherited variation, and disease recurrence

3. Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial–Mesenchymal Transition

4. Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer

5. Integrating pharmacogenomics data-driven prediction with bulk and single-cell RNAseq to demonstrate the efficacy of an NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer

6. Abstract 1638: Validation of a novel pan-Ras inhibitor, ADT-007, against lethal variants of prostate cancer

7. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion

8. Abstract 3856: Elucidating the role of fibroblasts in CRPC and ADPC progression using 3D engineered prostate cancer tissues

9. PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics

10. Abstract PO-126: Identification of distinct mRNA & microRNA signatures and mRNA-miRNA pairs associated with inter-ethnic differences in prostate cancer aggressiveness

11. Abstract 1355: A novel andrographolide analogue (3A.1) synergizes with Taxane derivatives in aggressive metastatic prostate cancers through upregulation of heatshock proteins and downregulation of MAT2A-mediated cell migration and invasion

12. Abstract 1354: Deciphering the functional basis of synergy between taxanes and TAK715: A novel repurposed drug candidate in treatment-refractory aggressive prostate cancer

13. Abstract A21: Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene

15. Abstract 5932: Targeting BRAF WT metastatic melanomas: Identifying ERBB4 mutations as biomarkers for novel combinatorial treatment strategies

16. Abstract 32: Development of a three-dimensional spheroid model system to more accurately evaluate schedule dependent mechanistic differences between metronomic and conventional dosing of topotecan

17. Abstract 2944: Identification of key transcriptomic and epigenomic factors influencing conventional and metronomic dosing in aggressive and non-aggressive prostate cancer

18. Abstract LB-267: Transcriptomic and epigenomic analysis of metastatic castration-resistant prostate cancer and a pan-cancer analysis of its genetic signatures

19. Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity

20. PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics.

Catalog

Books, media, physical & digital resources